

For further information: **Investor Relations** (Tel: +34 91 244 44 22) Marta Campos Martínez mcampos@rovi.es

Enervit Nutrition, joint venture of ROVI and Enervit, will distribute nutritional products and other nonpharmacological products in Spain and Portugal

Madrid, March 17th 2016 – Enervit Nutrition, S.L., joint venture participated by Laboratorios Farmacéuticos Rovi, S.A. ("ROVI") and the italian company Enervit, S.p.A., aims the joint distribution and co-marketing, by ROVI and Enervit, S.p.A., of dietary, food and nutrition products, as well as other non pharmacological products in the territories of Spain and Portugal.

Enervit, S.p.A is listed on the Milan Stock Exchange and leads the special nutrition market in Italy for those who do sports and have an interest in keeping fit.

Among the products owned by Enervit, S.p.A. that Enervit Nutrition, S.L. will market, ROVI had already been distributing some of them, in particular EnerZone, a range of products based in the principles of The Zone diet, under a previously signed agreement with Enervit, S.p.A.

Through this operation, ROVI intends to develop its business of nutritional products thanks to a lasting partnership that allows to both members of the joint venture to benefit from the synergies derived from their respective contributions to the same. Accordingly, ROVI will contribute with its knowledge, presence and portfolio of customers in the Spanish market as well as with its current licence rights over the EnerZone products. In turn, Enervit, S.p.A. will bring the extension of its licensing rights of EnerZone products, with regard to its duration, and the incorporation of new nutritional products, in order to ensure the innovative and extensive offering that this market demands.

1

Juan López-Belmonte Encina, Chief Executive Officer of ROVI, and Alberto Sorbini, Chairman of Enervit, S.p.A., commented: "this strategic alliance implies joining efforts to achieve our common objective; satisfying the needs of a society increasingly concerned for keeping a healthy and balanced diet that allows not only improving the physical appearance, but also helps to prevent diseases such as obesity, quite common in Spain during the last years. We are very enthusiastic with our presence in a sector that is at one of their highpoints and faces a promising future".

About ROVI

ROVI is a fully integrated Spanish specialty pharmaceutical company engaged in the research, development, in-licensing, manufacturing and marketing of small molecule and specialty biologic drugs. The Company has a diversified portfolio of products that it markets in Spain through its specialized sales force, calling on specialist physicians, hospitals and pharmacies. ROVI's portfolio of 30 principal marketed products is currently anchored by the internally-developed, second generation low molecular weight heparin, Bemiparin. ROVI's research and development pipeline is focused primarily on the expansion of applications, indications and alternative mechanisms of action for the heparin-derived products and other glycosaminoglycans and on the development of new controlled release mechanisms based on ISM® technology, with the aim of obtaining new pharmaceutical products that enable the regular administration of formulations which are administered daily in chronic and prolonged treatments. ROVI manufactures the active biological ingredient (Bemiparin) for its principal proprietary products and for injectable pharmaceutical products developed by its in-house research team, and utilizes its state-of-the-art filling and packaging capabilities to provide a broad array of toll manufacturing services to leading international pharmaceutical companies, primarily in the area of pre-filled syringes. In addition, ROVI provides contract manufacturing and packaging services of solid oral pharmaceutical dosage forms, using the most enhanced technology, Roller Compaction. Additional information about ROVI is available on the company's website: www.rovi.es

2